STATISTICAL COMPENDIUM: MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2004 MONTANA

LIST OF TABLES

OVERVIEW OF STUDY POPULATION

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

FOR ALL MEDICAID BENEFICIARIES

- TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC
- TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

FOR ALL NONDUAL BENEFICIARIES

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT. BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS. BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH. BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS

FOR DUAL ELIGIBLE BENEFICIARIES

- TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES. BY BASIS OF ELIGIBILITY
- TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY. BY BENEFICIARY CHARACTERISTIC
- TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC
- TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP
- TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND THERAPEUTIC CATEGORY
- TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP 10 DRUG GROUP
- TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC
- TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC
- TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

SUPPLEMENTAL TABLES

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

APPENDIX TABLES

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES

APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES

APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE D.2

CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY^{a, b}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

			Number of Ben	eficiaries					N	umber of Bene	efit Months		
Beneficiary						Other/							Other/
Characteristics	All	Aged	Disabled	Adults	Children	Unknown		All	Aged	Disabled	Adults	Children	Unknown
AII	17,486	8,786	7,526	1,166	6	2		171,512	82,953	74,785	13,688	66	20
Age													
5 and younger	0	0	0	0	0	0			0	0	0	0	0
6-14	6	0	6	0	0	0		72	0	72	0	0	0
15-20	29	0	24	0	5	0		327	0	267	0	60	0
21-44	3,189	3	2,626	559	1	0		33,391	36	26,857	6,492	6	0
45-64	4,531	6	4,021	502	0	2	0	45,088	72	39,036	5,960	0	20
65-74	3,525	2,742	712	71	0	0		33,807	25,798	7,179	830	0	0
75-84	3,173	3,028	115	30	0	0		30,262	28,734	1,170	358	0	0
85 and older	3,033	3,007	22	4	0	0		28,565	28,313	204	48	0	0
Unknown	0	0	0	0	0	0			0	0	0	0	0
Gender													
Female	11,144	6,480	4,096	564	2	2		110,726	62,669	41,441	6,572	24	20
Male	6,342	2,306	3,430	602	4	0	0	60,786	20,284	33,344	7,116	42	0
Unknown	0	0	0	0	0	0	U		0	0	0	0	0
Race													
White	15,605	7,986	6,535	1,076	6	2		152,220	74,994	64,498	12,642	66	20
African American	63	19	41	3	0	0	0	609	176	397	36	0	0
Other/unknown	1,818	781	950	87	0	0	Ü	18,683	7,783	9,890	1,010	0	0
Use of Nursing Facilities ^c													
Entire year	3,185	2,875	310	0	0	0		32,298	28,897	3,401	0	0	0
Part year	1,519	1,282	216	21	0	0		13,384	11,071	2,066	247	0	0
None	12,782	4,629	7,000	1,145	6	2		125,830	42,985	69,318	13,441	66	20
Maintenance Assistance Status													
Cash	6,139	1,871	4,255	13	0	0		66,849	20,674	46,054	121	0	0
Medically needy	8,219	5,785	2,434	0	0	0		70,719	50,816	19,903	0	0	0
Poverty-related	19	0	0	17	0	2		138	0	0	118	0	20
Other/unknown	3,109	1,130	837	1,136	6	0		33,806	11,463	8,828	13,449	66	0
Dual Medicare Status ^d													
Full dual, all year	17,486	8,786	7,526	1,166	6	2		171,512	82,953	74,785	13,688	66	20
Full dual, part year	0	0	0	0	0	0			0	0	0	0	0
Managed Care (MC) Status													
Fee-for-service (FFS) all year	17,486	8,786	7,526	1,166	6	2		171,512	82,953	74,785	13,688	66	20
FFS part year, with Rx claims	0	0	0	0	0	0	0		0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	5		0	0	0	0	0

- a. Table D.2 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- d. The "Full dual, all year" group contains beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefits during all months of Medicaid enrollment in 2004. The "Full dual, part year" group contains beneficiaries who had such benefits for some, but not all, months of their enrollment. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE D.3

ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC^{a, b}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

Beneficiary	Percentage with at			A D	Mean \$, All	Rx \$ as a Percentage of All Medicaid	Number of
Characteristics All	Least One Rx Mean N 87.2 %	48.5	Mean Rx \$	\$ per Rx \$62	Medicaid FFS \$ ^c	FFS \$ ^d 21.4 %	Beneficiaries
All	87.2 %	48.5	\$3,003	\$62	\$14,036	21.4 %	17,486
Age							
5 and younger	0.0	0.0	0	0	0	0.0	0
6-14	100.0	61.2	12,521	205	20,298	61.7	6
15-20	62.1	15.6	1,391	89	10,255	13.6	29
21-44	84.9	34.4	3,475	101	10,065	34.5	3,189
45-64	88.1	52.1	3,844	74	11,991	32.1	4,531
65-74	82.8	48.3	2,555	53	10,774	23.7	3,525
75-84	87.5	53.7	2,549	47	16,379	15.6	3,173
85 and older	93.4	52.9	2,243	42	22,629	9.9	3,033
Unknown	0.0	0.0	0	0	0	0.0	0
Basis of Eligibility ^e							
Aged	88.3	52.3	2,471	47	17,107	14.4	8,786
Disabled	85.2	45.6	3,669	81	11,353	32.3	7,526
Adults	92.4	39.2	2,714	69	8,160	33.3	1,166
Children	50.0	24.0	2,537	106	23,980	10.6	6
Unknown	100.0	9.5	1,373	145	15,287	9.0	2
Gender							
Female	90.1	54.4	3,103	57	14,645	21.2	11,144
Male	82.2	38.1	2,828	74	12,965	21.8	6,342
Unknown	0.0	0.0	0	0	0	0.0	0
Race							
White	89.3	50.5	3,094	61	14,397	21.5	15,605
African American	90.5	38.0	3,088	81	13,910	22.2	63
Other/unknown	69.4	31.7	2,216	70	10,942	20.3	1,818
Use of Nursing							
Facilities ^f							
Entire year	95.7	68.7	3,356	49	32,855	10.2	3,185
Part year	94.3	55.0	2,748	50	20,364	13.5	1,519
None	84.3	42.7	2,946	69	8,595	34.3	12,782
Maintenance Assistance Status							
Cash	82.1	39.2	2,696	69	6,636	40.6	6,139
Medically needy	90.0	55.7	3,189	57	18,689	17.1	8,219
Poverty related	94.7	20.2	1,192	59	4,911	24.3	19
Other/unknown	89.9	48.0	3,128	65	16,402	19.1	3,109

- a. Table D.3 includes beneficiaries represented by Cell G of Table 1.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.4

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT *PER BENEFIT MONTH*, BY BENEFICIARY CHARACTERISTIC^{a, b}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

					N	umber of Rx, Per	centage with:			_	Numbe	er
Beneficiary Characteristics	Mean Number of Rx 4.9		Rx \$ as a preentage of All Medicaid FFS \$^c	None 12.8 %	More than 0, but 1 or Less	More than 1, but 2 or Less 9.1 %	More than 2, but 5 or Less 27.1 %	More than 5, but 10 or Less 26.7 %	More than 10 10.0 %	Mean \$, All Medicaid FFS \$ ^d \$1,431	Beneficiaries	Benefit Months 171,512
All	4.9	\$306	21.4 %	12.8 %	14.4 %	9.1 %	27.1 %	26.7 %	10.0 %	\$1,431	17,486	171,512
Age												
5 and younger	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
6-14	5.1	1,043	61.7	0.0	0.0	16.7	33.3	50.0	0.0	1,692	6	72
15-20	1.4	123	13.6	37.9	20.7	17.2	20.7	3.4	0.0	909	29	327
21-44	3.3	332	34.5	15.1	27.6	12.5	24.2	15.7	4.9	961	3,189	33,391
45-64	5.2	386	32.1	11.9	14.0	8.7	27.4	25.9	12.2	1,205	4,531	45,088
65-74	5.0	266	23.7	17.2	12.3	8.2	24.7	27.1	10.6	1,123	3,525	33,807
75-84	5.6	267	15.6	12.5	9.1	8.0	27.2	31.1	12.0	1,717	3,173	30,262
85 and older	5.6	238	9.9	6.6	8.9	8.1	32.3	34.7	9.3	2,403	3,033	28,565
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Basis of Eligibility ^e												
Aged	5.5	262	14.4	11.7	9.9	8.1	28.0	31.3	11.0	1,812	8,786	82,953
Disabled	4.6	369	32.3	14.8	18.1	9.3	25.0	22.9	9.9	1,143	7,526	74,785
Adults	3.3	231	33.3	7.6	24.3	14.6	33.7	17.3	2.5	695	1,166	13,688
Children	2.2	231	10.6	50.0	0.0	0.0	50.0	0.0	0.0	2,180	6	66
Unknown	1.0	137	9.0	0.0	50.0	50.0	0.0	0.0	0.0	1,529	2	20
Gender												
Female	5.5	312	21.2	9.9	11.9	8.4	27.9	30.0	11.9	1,474	11,144	110,726
Male	4.0	295	21.8	17.8	18.7	10.2	25.7	21.0	6.6	1,353	6,342	60,786
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Race												
White	5.2	317	21.5	10.7	13.6	9.0	28.0	28.2	10.5	1,476	15,605	152,220
African American	3.9	320	22.2	9.5	20.6	15.9	30.2	15.9	7.9	1,439	63	609
Other/unknown	3.1	216	20.3	30.6	20.6	9.2	19.1	14.7	5.7	1,065	1,818	18,683
Use of Nursing												
Facilities ^t			40.0									
Entire year	6.8	331	10.2	4.3	5.7	6.3	28.7	38.7	16.3	3,240	3,185	32,298
Part year	6.2	312	13.5	5.7	8.1	7.2	29.2	36.3	13.6	2,311	1,519	13,384
None	4.3	299	34.3	15.7	17.3	10.0	26.4	22.6	8.0	873	12,782	125,830
Maintenance Assistance Status												
Cash	3.6	248	40.6	17.9	21.8	10.7	25.2	18.5	5.9	609	6,139	66,849
Medically needy	6.5	371	17.1	10.0	7.6	7.0	27.4	34.0	14.1	2,172	8,219	70,719
Poverty related	2.8	164	24.3	5.3	52.6	10.5	15.8	10.5	5.3	676	19	138
Other/unknown	4.4	288	19.1	10.1	17.5	11.3	30.0	23.9	7.2	1,508	3,109	33,806

Table D4

Dual Eligible Beneficiaries

- a. Table D.4 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. In seven states (DE, IA, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.
- d. In seven states (DE, IA, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.
- e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.5

AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC^{6, b, c}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

Beneficiary		All Rx		Patented Br	and-Name	Drugs	Off-Patent B	Brand-Name	Drugs	Gen	eric Drugs	
_	Number			Number			Number			Number		
Characteristics	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx	of Rx	Rx\$	\$ per Rx
All	4.9	\$306	\$62	1.7	\$210	\$122	0.3	\$21	\$59	2.9	\$75	\$26
Age												
5 and younger	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
6-14	5.1	1,043	205	2.0	891	449	0.5	70	136	2.6	82	32
15-20	1.4	123	89	0.7	102	147	0.1	2	32	0.6	19	31
21-44	3.3	332	101	1.2	249	200	0.2	23	104	1.8	60	33
45-64	5.2	386	74	1.9	267	142	0.3	28	86	3.0	90	30
65-74	5.0	266	53	1.8	174	99	0.3	17	52	2.9	75	25
75-84	5.6	267	47	1.9	177	91	0.4	15	38	3.3	74	23
85 and older	5.6	238	42	1.7	150	86	0.5	16	32	3.3	72	21
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Basis of Eligibility ^d												
Aged	5.5	262	47	1.9	171	92	0.4	16	39	3.2	74	23
Disabled	4.6	369	81	1.7	262	158	0.3	26	91	2.6	81	31
Adults	3.3	231	69	1.2	161	130	0.3	17	67	1.8	53	29
Children	2.2	231	106	1.2	193	160	0.1	3	52	0.9	34	38
Unknown	1.0	137	145	0.7	125	192	0.0	0	0	0.3	13	42
Gender												
Female	5.5	312	57	1.9	212	112	0.4	21	53	3.2	79	25
Male	4.0	295	74	1.4	206	149	0.3	21	75	2.3	68	29
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Race												
White	5.2	317	61	1.8	217	120	0.4	22	59	3.0	79	26
African American	3.9	320	81	1.5	246	159	0.2	14	59	2.1	60	28
Other/unknown	3.1	216	70	1.0	155	148	0.2	13	72	1.9	48	26
Use of Nursing Facilities ^e												
Entire year	6.8	331	49	2.2	213	98	0.6	23	39	4.0	94	24
· · · · · · · · · · · · · · · · · · ·	6.2	312	50	2.2	206	99	0.6	23 21	41	3.6	9 4 84	23
Part year None	4.3	299	69	1.6	210	134	0.3	20	75	2.5	69	23 28
Maintenance Assistance												
Status												
Cash	3.6	248	69	1.3	174	134	0.2	16	74	2.1	58	28
Medically needy	6.5	371	57	2.2	250	114	0.5	26	53	3.8	95	25
Poverty related	2.8	164	59	0.9	113	124	0.2	17	108	1.7	34	20
Other/unknown	4.4	288	65	1.6	198	127	0.3	20	61	2.5	69	28

- a. Table D.5 includes the beneficiaries represented by Cell G of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Montana, 0.7 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.6

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY^{a, b, c, d}

DUAL ELIGIBLE BENEFICIARIES. MONTANA. 2004

			•	per Benefit sper Benefit Month Among Users Users υ Φ Φ						\$ pe	· Rx			_		Users ^e	
Therapeutic Category	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total	Patented Brand-Name	Off-Patent Brand-Name	Generic	Total Number of Rx	Total Rx \$	Number	As a Percentage of Dual Benes	Number of Benefit Months
Anti-infective Agents	0.4	0.1	0.0	0.2	\$26	\$18	\$2	\$6	\$70	\$138	\$96	\$27	34,317	\$2,419,013	8,817	50.4 %	94,227
Biologicals	0.1	0.0	0.0	0.1	28	5	4	19	222	128	872	224	252	55,973	184	1.1	2,009
Antineoplastic Agents	0.6	0.1	0.0	0.5	89	61	0	27	149	547	131	57	3,015	449,848	503	2.9	5,080
Endocrine/Metabolic Drugs	1.2	0.5	0.1	0.6	50	36	3	12	42	77	21	19	97,558	4,097,215	7,905	45.2	81,981
Cardiovascular Agents	1.9	0.6	0.1	1.2	61	37	3	21	33	65	24	18	188,409	6,151,591	9,893	56.6	100,880
Respiratory Agents	0.9	0.5	0.0	0.3	57	50	0	7	67	95	49	23	50,878	3,421,958	5,672	32.4	59,722
Gastrointestinal Agents	0.7	0.1	0.0	0.5	49	23	2	25	70	164	42	47	47,170	3,309,220	6,303	36.0	67,361
Genitourinary Agents	0.6	0.5	0.0	0.2	42	36	1	5	66	80	56	28	19,337	1,268,337	2,811	16.1	29,892
CNS Drugs	1.5	0.6	0.1	0.8	134	101	8	26	92	165	95	33	148,756	13,688,887	9,873	56.5	102,012
Stimulants/Anti-obesity/Anorexia Miscellaneous Psychological/	0.7	0.4	0.1	0.3	74	55	4	15	100	151	76	45	2,879	286,693	363	2.1	3,890
Neurological Agents	0.8	0.7	0.0	0.0	166	163	0	3	221	226	89	95	8,379	1,851,234	1,072	6.1	11,141
Analgesics and Anesthetics	1.0	0.3	0.0	0.7	66	43	3	20	64	157	189	26	96,088	6,111,276	9,110	52.1	93,170
Neuromuscular Agents	1.1	0.3	0.2	0.6	83	42	21	20	77	150	104	33	63,067	4,828,923	5,495	31.4	58,161
Nutritional Products	0.7	0.0	0.0	0.7	14	0	1	13	19	23	18	19	27,920	540,088	3,698	21.1	37,781
Hematological Agents	0.9	0.2	0.3	0.5	68	55	7	6	74	288	24	14	27,273	2,017,737	2,927	16.7	29,802
Topical Products	0.4	0.2	0.0	0.2	18	12	1	5	45	74	49	22	26,077	1,169,272	5,997	34.3	64,963
Miscellaneous Products	0.6	0.3	0.1	0.3	151	101	21	29	253	381	270	114	3,003	758,658	473	2.7	5,021
Unknown Therapeutic Category	0.4	0.0	0.0	0.0	9	0	0	0	23	0	0	0	3,664	84,780	878	5.0	9,378
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	848,042	52,510,703	n.a.	n.a.	n.a.

- a. Table D.6 includes the beneficiaries represented by Cell G of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Montana, 0.7 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).
- e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.7

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP^{9, b, c}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

			Users		Ar	nong Users	
Top 10 Drug Groups	Total Medicaid Rx \$	Number of Users	As a Percentage of Dual Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	Rx:	\$ per Benefit Month
ANTIPSYCHOTICS	\$8,652,718	4,985	28.5 %	53,362	0.8	\$205	\$162
ANTIDEPRESSANTS	4,342,238	9,714	55.6	101,878	0.7	59	43
ANALGESICS - Narcotic	3,895,763	11,487	65.7	118,670	0.6	58	33
ANTICONVULSANT	3,823,921	4,593	26.3	49,127	0.9	92	78
ANTIASTHMATIC	2,684,043	6,573	37.6	69,295	0.5	71	39
ULCER DRUGS	2,661,507	6,456	36.9	68,840	0.7	59	39
ANTIDIABETIC	2,321,568	4,855	27.8	50,578	0.8	56	46
ANTIHYPERLIPIDEMIC	2,123,764	3,583	20.5	37,924	0.7	78	56
ANALGESICS - ANTI-INFLAMMATORY	1,881,741	4,233	24.2	45,591	0.5	89	41
NEUROLOGICAL	1,867,917	1,400	8.0	14,574	0.6	214	128
Total	34,255,180	57,879		609,839	n.a.	n.a.	n.a.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement; n.a. = not applicable.

a. Table D.7 includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.7A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED

AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

	All Top 10 Dr	ug Groups		ANTIPS	SYCHOTICS				ANTIDE	PRESSANTS		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of Dual Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Month	Number of Users	Users as % of Dual Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	406,362	\$34,255,180	4,985	28.5 %	53,362	0.8	\$162	9,714	55.6 %	101,878	0.7	\$43
Female	280,933	22,542,378	2,954	26.5	31,615	0.8	144	6,996	62.8	73,702	0.7	
Disabled	116,673	11,260,475	1,448	35.4	15,675	0.8	170	3,207	78.3	34,057	0.7	
5 and younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
6-14	23	1,418	0	0.0	0	0.0	0	0	0.0	0	0.0	
15-20	103	8,232	4	28.6	30	1.0	167	6	42.9	63	0.5	
21-44	29,250	3,179,701	553	47.3	5,929	0.8	174	924	79.0	9,955	0.6	
45-64	75,551	7,254,781	825	34.6	8,994	8.0	170	2,042	85.7	21,495	0.7	_
65-74	10,517	740,537	59	13.8	662	0.7	142	215	50.2	2,354	0.6	
75-84	1,088	66,765	4	4.9	38	0.7	56	16	19.8	153	0.5	
	141	9,041	3	15.8	22	0.7	46	4	21.1	37	0.5	
85 and older Other Eligibles	164,260	11,281,903	1,506	21.4	15,940	0.8	118	3,789	53.8	39,645	0.8	
5 and younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
6-14	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
15-20	20	1,988	2	100.0	24	0.2	21	2	100.0	24	0.3	
21-44	5,054	486,094	88	31.2	1,023	0.7	142	135	47.9	1,537	0.8	
45-64	5,750	501,899	80	33.3	960	0.9	170	111	46.3	1,317	1.0	
65-74	47,531	3,453,831	334	17.6	3,612	0.7	138	989	52.2	10,469	0.7	40
75-84	56,042	3,713,385	486	22.0	5,137	0.8	107	1,195	54.0	12,550	8.0	
85 and older	49,863	3,124,706	516	21.3	5,184	8.0	101	1,357	56.1	13,748	8.0	40
Male	125,429	11,712,802	2,031	32.0	21,747	0.8	189	2,718	42.9	28,176	0.7	42
Disabled	69,306	7,517,378	1,340	39.1	14,394	0.8	216	1,553	45.3	16,344	0.7	
Disableu	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
5 and younger	17	814	0	0.0	0	0.0	0	0	0.0	0	0.0	
6-14	56	7,627	1	10.0	12	1.0	415	2	20.0	24	0.5	
15-20	26,160	3,267,914	759	52.1	8,240	0.8	206	627	43.1	6,698	0.6	
21-44	37,310	3,824,871	541	33.0	5,727	0.9	232	820	50.0	8,556	0.7	
45-64	5,181	348,035	30	10.6	307	1.2	182	92	32.4	949	0.8	
65-74	571	67,705	9	26.5	108	0.8	246	11	32.4	111	0.6	
75-84	11	412	0	0.0	0	0.0	0	1	33.3	6	0.3	
85 and older Other Eligibles	56,123	4,195,424	691	23.7	7,353	0.8	136	1,165	40.0	11,832	0.8	
	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
5 and younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
6-14	81	11,551	1	33.3	12	1.8	198	1	33.3	12	1.0	79
15-20	4,610	550,745	91	32.4	1,092	0.9	190	90	32.0	1,066	0.8	
21-44	6,457	630,716	113	41.9	1,355	0.9	178	106	39.3	1,271	0.9	56
45-64	18,033	1,339,569	170	18.5	1,824	0.8	146	321	34.9	3,288	0.7	39
65-74	15,912	989,410	178	21.0	1,793	0.8	95	349	41.2	3,353	0.8	
75-84	11,030	673,433	138	23.4	1,277	0.7	88	298	50.4	2,842	0.8	
85 and older	·									,		
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

- a. Table D.7A includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.7B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

		ANALGE	SICS - Narcotio	;			ANTICO	ONVULSANT				ANTIA	STHMATIC		
Beneficiary Characteristics	Number of Users	Users as % of Dual Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of Dual Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of Dual Benes	Number of Benefit Months Among Users	of Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	11,487	65.7 %	118,670	0.6	\$33	4,593	26.3 %	49,127	0.9	\$78	6,573	37.6 %	69,295	0.5	\$39
Female	8,119	72.9	84,817	0.6	33	2,941	26.4	31,566	0.8	71	4,602	41.3	49,153	0.5	
Disabled	3,618	88.3	38,725	0.6	34	1,646	40.2	17,640	0.8	80	1,917	46.8	20,659	0.5	
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
6-14	1	50.0	12	0.3	3	1	50.0	12	0.5	59	0	0.0	0	0.0	
15-20	9	64.3	108	0.1	2	0	0.0	0	0.0	0	6	42.9	72	0.2	
21-44	1,041	89.0	11,338	0.5	36	573	49.0	6,187	0.8	93	446	38.1	4,904	0.4	
45-64	2,195	92.1	23,212	0.6	35	971	40.8	10,377	0.8	76 20	1,218	51.1	12,958	0.5	
65-74	316	73.8	3,444	0.5	22	93	21.7	996	0.6	39	216	50.5	2,389	0.5	
75-84	51	63.0	563	0.5	33	8	9.9	68	0.6	17	31	38.3	336	0.4	
85 and older Other Eligibles	5 4,501	26.3 63.9	48 46,092	0.2 0.6	1 31	0 1,295	0.0	0 13,926	0.0	0 60	0 2,685	0.0 38.1	0 28,494	0.0 0.6	
Other Eligibles	4,501	0.0	40,092	0.0	0	1,295	18.4 0.0	13,926	0.0	0	2,665	0.0	20,494	0.0	
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
6-14	0	0.0	0	0.0	0	1	50.0	12	0.8	85	0	0.0	0	0.0	
15-20	119	42.2	1,294	0.0	6	126	44.7	1,455	1.0	124	46	16.3	535	0.0	
21-44	60	25.0	709	0.2	5	100	41.7	1,433	1.1	98	47	19.6	560	0.4	
45-64	1,319	69.7	13,695	0.5	33	402	21.2	4,314	0.8	55	970	51.2	10,251	0.6	
65-74	1,469	66.4	15,159	0.6	33	382	17.3	4,027	0.8	43	881	39.8	9,409	0.6	
75-84	1,534	63.4	15,135	0.6	32	284	11.7	2,931	0.9	43	741	30.6	7,739	0.5	35
85 and older	1,004	00.4	10,200	0.0	02	204		2,501	0.0	70	741	00.0	7,700	0.0	00
Male	3,368	53.1	33,853	0.5	34	1,652	26.0	17,561	0.9	90	1,971	31.1	20,142	0.6	
Disabled	2,043	59.6	21,027	0.5	37	1,028	30.0	10,828	0.9	91	941	27.4	9,932	0.5	35
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	25.0	12	0.1	2
15-20	1	10.0	12	0.2	1	1	10.0	12	1.0	22	2	20.0	19	0.4	
21-44	806	55.4	8,521	0.5	28	472	32.4	5,026	0.8	93	312	21.4	3,349	0.4	
45-64	1,078	65.8	10,910	0.6	45	515	31.4	5,374	0.9	92	493	30.1	5,189	0.5	
65-74	143	50.4	1,436	0.6	33	36	12.7	383	1.0	50	124	43.7	1,271	0.7	48
75-84	14	41.2	139	0.3	13	4	11.8	33	1.0	104	7	20.6	74	0.6	
	1	33.3	9	0.6	5	0	0.0	0	0.0	0	2	66.7	18	0.2	
85 and older Other Eligibles	1,325	45.5	12,826	0.5	28	624	21.4	6,733	1.0	88	1,030	35.4	10,210	0.6	
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
15-20	0 44	0.0 15.7	0 518	0.0	0 60	4 109	133.3 38.8	48	0.8 1.2	150 142	1 14	33.3	12 163	0.7	74 18
21-44	44 68	15.7 25.2	518 791	0.2 0.2	3	109		1,298 1,607	1.2	142 112	14 42	5.0 15.6	504	0.3 0.6	
45-64	485	25.2 52.7	4,745	0.2	36	176	49.6 19.1	1,841	1.1	71	42 391	15.6 42.5	3,783	0.6	
65-74	405	52. <i>1</i> 49.1	3,904	0.6	25	176	14.3	1,041	0.8	53	336	42.5 39.7	3,763	0.6	
75-84	312	49.1 52.8	2,868	0.6	25 21	80	14.3	731	0.8	38	246	39.7 41.6	2,431	0.6	
85 and older	312	JZ.0	2,000	0.5	۷1	60	13.3	131	0.9	30	240	41.0	۷,43۱	0.0	41
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

- a. Table D.7B includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.7C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS

SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

		ULCE	R DRUGS				ANTII	DIABETIC				ANTIHYP	ERLIPIDEMIC)	
Beneficiary Characteristics	Number of Users	Users as % of Dual Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of Dual Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per Benefit Month	Number of Users	Users as % of Dual Benes	Number of Benefit Months Among Users	of Rx	Mean Rx \$ per
All	6,456	36.9 %	68,840	0.7	\$39	4,855	27.8 %	50,578	0.8	\$46	3,583	20.5 %	37,924	0.7	\$56
Female	4,519	40.6	48,425	0.7	39	3,347	30.0	35,271	0.8	45	2,468	22.1	26,356	0.7	56
Disabled	1,759	42.9	19,235	0.6	42	1,147	28.0	12,403	0.8	51	992	24.2	10,771	0.7	52
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
5 and younger 6-14	2	100.0	24	0.2	4	0	0.0	0	0.0	0	1	50.0	12	0.8	50
15-20	0	0.0	0	0.0	0	2	14.3	6	0.7	82	0	0.0	0	0.0	0
21-44	392	33.5	4,334	0.5	37	162	13.8	1,770	0.7	46	124	10.6	1,372	0.6	44
45-64	1,128	47.4	12,225	0.6	45	759	31.9	8,148	0.8	54	693	29.1	7,447	0.7	55
65-74	205	47.9	2,314	0.6	37	193	45.1	2,143	0.8	48	155	36.2	1,715	0.6	47
75-84	27	33.3	285	0.4	20	26	32.1	284	0.6	38	18	22.2	213	0.6	48
	5	26.3	53	0.6	49	5	26.3	52	0.7	35	1	5.3	12	0.1	5
85 and older Other Eligibles	2,760	39.2	29,190	0.7	37	2,200	31.2	22,868	0.8	41	1,476	20.9	15,585	0.8	59
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
15-20	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
21-44	64	22.7	747	0.7	40	23	8.2	274	0.8	47	12	4.3	144	8.0	72
45-64	70	29.2	820	8.0	49	36	15.0	432	0.9	60	32	13.3	384	0.8	60
65-74	753	39.8	7,997	0.6	36	745	39.4	7,891	0.8	46	599	31.6	6,339	0.7	58
75-84	892	40.3	9,620	0.7	36	833	37.7	8,620	0.9	40	578	26.1	6,161	0.8	60
85 and older	981	40.5	10,006	0.7	37	563	23.3	5,651	0.8	34	255	10.5	2,557	0.8	58
Male	1,937	30.5	20,415	0.7	39	1,508	23.8	15,307	0.8	48	1,115	17.6	11,568	0.7	55
Disabled	965	28.1	10,307	0.6	41	760	22.2	7,881	0.8	54	629	18.3	6,577	0.7	52
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
5 and younger	2	50.0	24	0.7	33	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	2	20.0	24	0.4	10	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	361	24.8	4,004	0.5	36	180	12.4	1,923	0.8	57	177	12.2	1,978	0.6	49
21-44	498	30.4	5,202	0.7	47	480	29.3	4,912	0.8	55	376	22.9	3,802	0.7	54
45-64 65-74	94	33.1	970	0.7	38	82	28.9	845	0.8	45	73	25.7	762	0.7	54
75-84	8	23.5	83	0.6	38	18	52.9	201	0.8	30	3	8.8	35	1.0	73
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	
85 and older Other Eligibles	972	33.4	10,108	0.7	36	748	25.7	7,426	0.8	42	486	16.7	4,991	0.8	59
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
15-20	1	33.3	12	0.2	10	0	0.0	0	0.0	0	0	0.0	0	0.0	
21-44	66	23.5	787	0.9	44	17	6.0	204	0.8	54	23	8.2	276	0.7	56
45-64	94	34.8	1,114	0.8	42	28	10.4	329	0.7	54	49	18.1	581	0.9	66
65-74	292	31.7	3,028	0.6	36	326	35.4	3,313	0.8	43	218	23.7	2,234	0.7	57
75-84	280	33.1	2,771	0.7	34	250	29.5	2,357	0.9	43	163	19.2	1,597	0.8	62
85 and older	239	40.4	2,396	0.7	35	127	21.5	1,223	8.0	34	33	5.6	303	8.0	54
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

- a. Table D.7C includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.7D MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

	ANAL	GESICS - A	NTI-INFLAM	MATORY		MISC PSYCH	OTHERAP	EUTIC AND N	NEUROLO	GICAL		
Beneficiary Characteristics	Number of Users 4,233	Users as % of Dual Benes 24.2 %	Number of Benefit Months Among Users 45,591	of Rx	Rx \$ per	Number of Users 1,400	Users as % of Dual Benes 8.0 %	Number of Benefit Months Among Users 14,574	of Rx	Mean Rx \$ per Benefit Month	Number of Beneficiaries E 17,486	Number of Benefit Months 171,512
	,		•								·	
Female	3,056 1,397	27.4 34.1	33,169 15,362	0.5 0.4	46 50	1,004 301	9.0 7.3	10,534 3,293	0.6 0.4	142 254	11,144 4,096	110,726 41,441
Disabled	1,397	0.0	15,362	0.4	0	0	0.0	3,293	0.4	254	4,096	41,441
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	24
6-14	4	28.6	48	0.0	1	0	0.0	0	0.0	0	14	157
15-20	374	32.0	4,171	0.1	35	81	6.9	893	0.3	196	1,170	11,972
21-44	865	36.3	9,436	0.5	59	199	8.4	2,158	0.5	294	2,382	23,747
45-64	136	31.8	1,499	0.3	38	18	4.2	2,136	0.5	114	428	4,541
65-74	150	18.5	1,499	0.4	34	1	1.2	9	0.5	52	81	820
75-84	3	15.8	33	0.5	32	2	10.5	17	0.4	87	19	180
85 and older Other Eligibles	1,659	23.5	17,807	0.5	42	703	10.5	7,241	0.0	91	7,048	69,285
Other Eligibles	0	0.0	0	0.0	0	0	0.0	0	0.0	0	7,048	09,200
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	2	24
15-20	75	26.6	859	0.0	7	4	1.4	44	0.0	19	282	3,231
21-44	60	25.0	716	0.5	17	18	7.5	213	0.5	88	240	2,855
45-64	491	25.0 25.9	5,264	0.5	52	108	7.5 5.7	1,178	0.5	95	1,893	,
65-74	556	25.9 25.1	5,264	0.5	52 42	273	12.3	,	0.8	95 94	2,211	18,269
75-84	477	19.7	5,900	0.5	42	300	12.3	2,857 2,949	0.6	9 4 88	2,420	21,643 23,263
85 and older	411	19.7	5,000	0.0	41	300	12.4	2,949	0.7	00	2,420	23,203
Male	1,177	18.6	12,422	0.4	30	396	6.2	4,040	0.5	93	6,342	60,786
Disabled	687	20.0	7,283	0.4	32	152	4.4	1,603	0.4	111	3,430	33,344
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	4	48
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	10	110
15-20	277	19.0	2,977	0.3	22	65	4.5	692	0.3	112	1,456	14,885
21-44	360	22.0	3,766	0.5	38	79	4.8	834	0.4	118	1,639	15,289
45-64	44	15.5	477	0.3	18	5	1.8	41	0.3	40	284	2,638
65-74	6	17.6	63	0.4	244	3	8.8	36	0.6	35	34	350
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	3	24
85 and older Other Eligibles	490	16.8	5,139	0.5	27	244	8.4	2,437	0.7	80	2,912	27,442
_	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
5 and younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
6-14	0	0.0	0	0.0	0	0	0.0	0	0.0	0	3	36
15-20	22	7.8	264	0.3	4	4	1.4	48	0.4	36	281	3,303
21-44	44	16.3	528	0.5	19	5	1.9	50	0.2	25	270	3,197
45-64	166	18.0	1,718	0.5	29	54	5.9	566	0.6	84	920	8,359
65-74	165	19.5	1,705	0.5	29	87	10.3	845	0.6	70	847	7,449
75-84	93	15.7	924	0.5	28	94	15.9	928	0.7	93	591	5,098
85 and older												•
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

- a. Table D.7D includes the beneficiaries represented by Cell G of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2004. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

TABLE D.8

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BENEFICIARY CHARACTERISTIC^{a, b}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

				Benefit Months Among All-
Beneficiary		Number of Rx per Benefit	Number of All-Year Nursing	Year Nursing Facility
Characteristics	Rx \$ per Benefit Month	Month	Facility Residents	Residents
All	\$331	6.8	3,185	32,298
Age				
0-64	496	7.6	253	2,774
65-74	449	8.1	398	4,177
75-84	343	7.1	963	9,647
85 and older	263	6.1	1,571	15,700
Unknown	0	0.0	0	0
Gender				
Female	328	6.9	2,284	23,467
Male	338	6.5	901	8,831
Unknown	0	0.0	0	0
Race				
White	330	6.8	3,010	30,577
African American	370	5.5	6	72
Other/unknown	348	7.2	169	1,649
Basis of Eligibility ^c				
Aged	313	6.7	2,875	28,897
Disabled	484	7.6	310	3,401
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

a. Table D.8 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their 2004 Medicaid enrollment. A total of 1,519 beneficiaries who were in nursing facilities for part of their enrollment and their 13,384 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible ebecause of disability or blindness. The children's group includes children receiving foster care and adoptive services.

TABLE D.9

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,

BY BRAND STATUS AND THERAPEUTIC CATEGORY a, b, c, d, e DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

	Number of Rx per Benefit \$ per Benefit Month Month Among Users Among Users									¢ nor	Dv					Users	
	IVIC	Brand-	Brand-	15		Brand-	Brand-			Brand-	Brand-			-		As a Percentage of Dual All- Year	
Therapeutic Category	Total	Patented Name	Off-Patent Name	Generic	Total	Patented Name	Off-Patent Name	Generic	Total	Patented Name	Off-Patent Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.3	0.1	0.0	0.2	\$14	\$8	\$1	\$5	\$42	\$69	\$62	\$23	7,204	\$300,184	1,930	60.6 %	21,001
Biologicals	0.1	0.0	0.0	0.1	3	0	0	3	26	14	33	31	173	4,542	129	4.1	1,419
Antineoplastic Agents	0.6	0.1	0.0	0.5	77	37	0	40	119	365	141	73	792	94,317	126	4.0	1,227
Endocrine/Metabolic Drugs	1.4	0.5	0.1	0.7	53	38	3	13	39	74	18	18	23,820	924,324	1,639	51.5	17,312
Cardiovascular Agents	2.1	0.4	0.1	1.5	53	25	3	26	25	58	20	17	49,604	1,259,482	2,271	71.3	23,564
Respiratory Agents	0.9	0.5	0.0	0.4	55	44	0	10	61	93	54	24	9,758	596,862	1,020	32.0	10,946
Gastrointestinal Agents	0.9	0.1	0.1	0.7	42	11	2	29	49	130	28	41	14,079	688,697	1,508	47.3	16,298
Genitourinary Agents	0.8	0.5	0.0	0.2	50	42	2	6	65	78	52	30	6,480	424,121	792	24.9	8,547
CNS Drugs	1.5	0.8	0.1	0.7	118	88	8	22	76	116	72	33	36,466	2,779,702	2,244	70.5	23,584
Stimulants/Anti-obesity/Anorexia Miscellaneous Psychological/	0.9	0.1	0.1	0.7	32	14	2	15	34	110	30	21	378	12,759	37	1.2	401
Neurological Agents	1.0	1.0	0.0	0.0	150	150	0	0	153	154	61	45	4,248	651,754	413	13.0	4,342
Analgesics and Anesthetics	1.2	0.4	0.0	0.8	63	47	1	15	53	123	109	19	21,441	1,141,867	1,751	55.0	18,125
Neuromuscular Agents	1.3	0.3	0.3	0.7	79	27	23	29	60	98	74	39	12,939	771,939	894	28.1	9,766
Nutritional Products	0.9	0.0	0.1	8.0	18	0	1	17	20	22	18	20	10,188	204,566	1,098	34.5	11,527
Hematological Agents	1.3	0.2	0.5	0.5	51	35	9	7	40	160	18	12	10,851	436,074	814	25.6	8,570
Topical Products	0.5	0.2	0.0	0.3	19	13	1	6	39	65	41	21	8,541	334,953	1,573	49.4	17,333
Miscellaneous Products	0.2	0.1	0.0	0.1	17	8	2	7	72	86	127	54	479	34,676	190	6.0	2,080
Unknown Therapeutic Category	0.5	0.0	0.0	0.0	8	0	0	0	18	0	0	0	1,522	26,823	305	9.6	3,319
TOTAL NO. OF RX AND RX \$	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	218,963	10,687,642	n.a.	n.a.	n.a.

a. Table D.9 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 1,519 beneficiaries who were in nursing facilities for part of their enrollment and their 13,384 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2004. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

In Montana, 0.7 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.10

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY TOP-10 DRUG GROUP^{a, b, c, d}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

			Users		A	mong Users	
	_		As a Percentage of All-Year	_			
		Number of	Nursing Facility	Number of	Number of Rx per	• -	Rx \$ per Benefit
Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Users	Residents	Benefit Months	Benefit Month	\$ per Rx	Month
ANTIPSYCHOTICS	\$1,524,842	1,080	33.9 %	11,674	0.9	\$154	\$131
ANTIDEPRESSANTS	1,125,986	2,178	68.4	23,097	0.9	56	49
ANALGESICS - Narcotic	875,780	2,059	64.6	21,337	0.8	54	41
MISC PSYCHOTHERAPEUTIC AND							
NEUROLOGICAL	652,313	509	16.0	5,401	0.8	153	121
ULCER DRUGS	579,677	1,404	44.1	15,134	0.8	48	38
ANTIASTHMATIC	511,537	1,128	35.4	12,221	0.6	65	42
ANTICONVULSANT	499,444	727	22.8	7,976	1.1	60	63
ANTIDIABETIC	483,083	1,050	33.0	11,288	1.0	45	43
ANTIHYPERTENSIVE	368,082	1,243	39.0	13,022	0.9	31	28
MISC. ENDOCRINE	363,407	553	17.4	6,013	0.8	80	60
Total	6,984,151	11,931		127,163	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2004 file for Montana, released by CMS in 12/2007. This table was produced on 03/25/2008.

a. Table D.10 includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 1,519 beneficiaries who were in nursing facilities for part of their enrollment and their 13,384 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.10A

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST

AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

	All Top 10 Dru	ug Groups		ANTIPS	SYCHOTICS			_	ANTIDE	PRESSANTS		
Beneficiary Characteristics	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	106,025	\$6,984,151	1,080	33.9 %	11,674	0.9	\$131	2,178	68.4 %	23,097	0.9	\$49
Female	77,424	5,048,211	758	33.2	8,250	0.8	125	1,623	71.1	17,355	0.9	48
Disabled	6,920	658,490	82	53.6	960	1.0	179	121	79.1	1.348	0.9	64
Disabled r	5.753	554.555	66	51.2	771	1.0	179	101	78.3	1.129	0.9	67
64 or younge	1,164	103,766	16	69.6	189	0.8	178	19	82.6	218	0.9	49
65-74	3	169	0	0.0	0	0.0	0	1	100.0	1	1.0	9
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	70,504	4,389,721	676	31.7	7,290	0.8	117	1,502	70.5	16,007	0.9	47
Other Engines	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younge	9,523	647,295	93	46.7	987	0.8	139	174	87.4	1,876	0.9	50
65-74	25.731	1,658,825	259	38.7	2,869	0.9	126	507	75.8	5,448	0.9	51
75-84	35,250	2,083,601	324	25.7	3,434	0.8	104	821	65.0	8,683	0.8	44
85 and older	,	, ,			•		_	_		•		
Male	28,601	1,935,940	322	35.7	3,424	0.9	145	555	61.6	5,742	0.9	50
Disabled	6,118	503,047	70	44.6	804	1.0	216	100	63.7	1,117	0.9	53
r 64 or younge	4,618	399,040	51	41.1	583	0.9	204	74	59.7	828	0.9	53
65-74	1,263	70,220	14	50.0	161	1.3	182	23	82.1	253	1.1	53
75-84	237	33,787	5	100.0	60	1.3	428	3	60.0	36	8.0	48
	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	22,483	1,432,893	252	33.9	2,620	0.8	124	455	61.2	4,625	0.9	49
r 64 or younge	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	6,193	475,228	68	45.9	772	1.0	187	100	67.6	1,107	0.9	56
75-84	8,203	484,935	97	33.7	1,030	8.0	100	179	62.2	1,742	0.9	45
85 and older	8,087	472,730	87	28.2	818	8.0	94	176	57.1	1,776	0.9	48
Unknown	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

a. Table D.10A includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 1,519 beneficiaries who were in nursing facilities for part of their enrollment and their 13,384 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had feefor-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.10B

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY

AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d}

DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

		ANALGES	SICS - Narcoti	ic		MISC PSYC	HOTHERAP	EUTIC AND N	NEUROLO	GICAL	ULCER DRUGS				
Beneficiary Characteristics	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
All	2,059	64.6 %	21,337	0.8	\$41	509	16.0 %	5,401	0.8	\$121	1,404	44.1 %	15,134	0.8	\$38
Female Disabled	1,569 102	68.7 66.7	16,401 1,119	0.8 0.7	44 39	369 22	16.2 14.4	3,915 249	0.8 1.0	123 496	1,016 87	44.5 56.9	11,013 1,002	0.8	39 51
r 64 or younge	90	69.8	981	0.7	42	17	13.2	189	1.0	555	68	52.7	795	0.8	52
65-74 75-84	12 0	52.2 0.0	138 0	1.0 0.0	18 0	5 0	21.7 0.0	60 0	0.8 0.0	308 0	18 1	78.3 100.0	206 1	0.7 1.0	45 126
85 and older Other Eligibles	0 1,467	0.0 68.8	0 15,282	0.0 0.8	0 44	0 347	0.0 16.3	0 3,666	0.0 0.8	0 97	0 929	0.0 43.6	0 10,011	0.0 0.8	0 37
r 64 or younge	0 179	0.0 89.9	0 1,804	0.0 0.9	0 69	0 28	0.0 14.1	0 311	0.0 0.7	0 81	0 103	0.0 51.8	0 1,129	0.0 0.9	0 39
65-74 75-84	454	67.9	4,824	0.9	48	139	20.8	1,494	0.8	105	296	44.2	3,304	0.8	36
85 and older	834	66.0	8,654	0.7	36	180	14.3	1,861	0.8	94	530	42.0	5,578	0.8	38
Male Disabled	490 96	54.4 61.1	4,936 1,073	0.7 0.6	33 25	140 12	15.5 7.6	1,486 144	8.0 8.0	116 333	388 67	43.1 42.7	4,121 760	0.8 0.9	38 50
r 64 or younge	75 20	60.5 71.4	852 218	0.7 0.5	29 9	11 0	8.9 0.0	132 0	0.8	362 0	49 16	39.5 57.1	560 176	0.9 1.0	50 41
65-74 75-84	1	20.0	3	0.7	14	1	20.0	12	1.1	14	2	40.0	24	1.0	108
85 and older Other Eligibles	0 394	0.0 53.0	0 3,863	0.0 0.7	0 35	0 128	0.0 17.2	0 1,342	0.0 0.8	0 93	0 321	0.0 43.1	0 3,361	0.0 0.8	0 35
r 64 or younge	0 85	0.0 57.4	0 909	0.0 0.7	0 36	0 28	0.0 18.9	0 300	0.0 0.8	0 91	0 74	0.0 50.0	0 811	0.0 0.7	0 37
65-74 75-84	152	52.8	1,424	0.8	43	44	15.3	445	0.7	81	106	36.8	1,084	0.8	35
85 and older	157	51.0	1,530	0.6	27	56	18.2	597	8.0	102	141	45.8	1,466	8.0	34
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

a. Table D.10B includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 1,519 beneficiaries who were in nursing facilities for part of their enrollment and their 13,384 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.10C

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

	ANTIASTHMATIC					ANTICO	DNVULSANT			ANTIDIABETIC					
Beneficiary	Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months Among	Mean Number	Mean	Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months Among	Mean Number	Mean	Number of	Users as % of All-Year Nursing Facility	Number of Benefit Months Among	Mean Number	Mean
Characteristics	Users	Residents	Users	of Rx	Rx \$	Users	Residents	Users	of Rx	Rx \$	Users	Residents	Users	of Rx	Rx \$
All	1,128	35.4 %	12,221	0.6	\$42	727	22.8 %	7,976	1.1	\$63	1,050	33.0 %	11,288	1.0	\$43
Female	769	33.7	8,458	0.6	40	467	20.4	5,120	1.0	56	759	33.2	8,147	0.9	42
Disabled	59	38.6	683	0.7	49	89	58.2	1,007	1.2	82	55	35.9	633	1.1	56
r	49	38.0	567	0.7	48	77	59.7	880	1.2	86	41	31.8	468	1.1	55
64 or younge	10	43.5	116	0.5	54	11	47.8	126	1.0	53	14	60.9	165	1.0	58
65-74	0	0.0	0	0.0	0	1	100.0	1	1.0	34	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	710	33.3	7,775	0.6	39	378	17.7	4,113	1.0	50	704	33.0	7,514	0.9	40
r	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younge	81	40.7	852	0.8	59	78	39.2	874	1.1	50	118	59.3	1,342	0.9	49
65-74	240	35.9	2,660	0.7	42	141	21.1	1,530	0.9	50	270	40.4	2,962	1.0	42
75-84	389	30.8	4,263	0.5	33	159	12.6	1,709	0.9	49	316	25.0	3,210	0.9	35
85 and older	050	00.0	0.700	0.7	4-	000	00.0	0.050			004	00.0	0.444	4.0	40
Male	359	39.8	3,763	0.7	47	260	28.9	2,856	1.1	75	291	32.3	3,141	1.0	46
Disabled	43	27.4	499	0.7	37	90	57.3	1,039	1.3	91	50	31.8	558	1.0	50
r 64 or younge	38	30.6	439	0.7	39	76	61.3	887	1.3	96	34	27.4	396	1.0	54
65-74	5	17.9	60	0.7	23	12	42.9	137	1.2	61	11	39.3	102	0.9	44
75-84	0	0.0	0	0.0	0	2	40.0	15	1.1	73	5	100.0	60	0.9	33
	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older Other Eligibles	316	42.5	3,264	0.7	48	170	22.8	1,817	1.1	65	241	32.4	2,583	1.0	45
r 64 or younge	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	72	48.6	751	0.8	63	72	48.6	792	1.2	87	55	37.2	630	1.1	51
75-84	115	39.9	1,199	0.7	40	52	18.1	539	1.0	60	108	37.5	1,136	0.9	45
75-84 85 and older	129	41.9	1,314	0.6	47	46	14.9	486	0.9	36	78	25.3	817	1.0	41
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2004 file for Montana, released by CMS in 12/2007. This table was produced on 03/25/2008.

- a. Table D.10C includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 1,519 beneficiaries who were in nursing facilities for part of their enrollment and their 13,384 benefit months were excluded from the analysis.
- b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.
- c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.
- d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.10D

MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE^{a, b, c, d} DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

		ANTIHY	PERTENSIVE				MISC. I	ENDOCRINE				Benefit
		Users as % of All-Year Nursing	Number of Benefit Months	Mean			Users as % of All-Year Nursing	Number of Benefit Months	Mean		All-Year Nursing	Months Among All- Year Nursing
Beneficiary	Number of	Facility	Among	Number	Mean	Number of	Facility	Among	Number	Mean	Facility	Facility
Characteristics	Users	Residents	Users	of Rx	Rx\$	Users	Residents	Users	of Rx	Rx\$	Residents	Residents
All	1,243	39.0 %	13,022	0.9	\$28	553	17.4 %	6,013	0.8	\$60	3,185	32,298
Female	907	39.7	9,574	0.9	28	498	21.8	5,454	0.8	60	2,284	23,467
Disabled	32	20.9	384	0.9	33	24	15.7	279	0.8	71	153	1,699
r	25	19.4	300	1.0	34	19	14.7	219	0.8	71	129	1,432
64 or younge	7	30.4	84	8.0	28	5	21.7	60	1.0	70	23	266
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	1
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older Other Eligibles	875	41.1	9,190	0.9	28	474	22.2	5,175	0.7	60	2,131	21,768
r	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
64 or younge	92	46.2	963	0.9	29	44	22.1	483	0.7	73	199	2,050
65-74	285	42.6	3,008	1.0	29	162	24.2	1,755	0.8	64	669	6,913
75-84	498	39.4	5,219	0.9	28	268	21.2	2,937	0.7	55	1,263	12,805
85 and older			•								,	•
Male	336	37.3	3,448	0.9	28	55	6.1	559	0.8	64	901	8,831
Disabled	48	30.6	542	0.9	26	4	2.5	48	0.6	44	157	1,702
r 64 or vounge	33	26.6	369	0.8	26	4	3.2	48	0.6	44	124	1,342
64 or younge 65-74	13	46.4	149	1.2	28	0	0.0	0	0.0	0	28	309
	2	40.0	24	1.0	21	0	0.0	0	0.0	0	5	51
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older Other Eligibles	288	38.7	2,906	0.9	28	51	6.9	511	0.8	65	744	7,129
r	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
64 or younge	64	43.2	702	0.9	31	9	6.1	99	0.8	101	148	1,552
65-74	105	36.5	1,045	0.9	27	19	6.6	176	0.8	54	288	2,682
75-84	119	38.6	1,159	0.9	28	23	7.5	236	0.9	59	308	2,895
85 and older												
Unknown	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2004 file for Montana, released by CMS in 12/2007. This table was produced on 03/25/2008.

a. Table D.10D includes the beneficiaries represented by Cell H of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2004. A total of 1,519 beneficiaries who were in nursing facilities for part of their enrollment and their 13,384 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2004. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2004 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615 (October 26, 2007).

TABLE D.11

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG DUALS, BY BENEFICIARY CHARACTERISTIC^{a,b}

MONTANA, 2004

	Number of	Percentage of						Part D Excluded	
	Beneficiaries with	Beneficiaries with		Total Number	Part D			Rx \$ as a	
Beneficiary	at Least One Part	at Least One Part			Excluded Rx \$	Total Part D	\$ per Part D	Percentage of All	Total Number
Characteristics	D Excluded Rx		per Beneficiary		per Beneficiary		Excluded Rx		of Beneficiaries
All	9,671	55.3 %	5.9	102,750	\$112	\$1,966,631	\$19	3.7 %	17,486
Age									
5 and younger	0	0.0	0.0	0	0	0	0	0.0	0
6-14	6	100.0	4.8	29	212	1,270	44	1.7	6
15-20	9	31.0	1.6	47	47	1,358	29	3.4	29
21-44	1,552	48.7	4.6	14,710	88	281,552	19	2.5	3,189
45-64	2,635	58.2	7.0	31,583	136	618,459	20	3.6	4,531
65-74	1,888	53.6	5.7	20,057	114	402,645	20	4.5	3,525
75-84	1,791	56.4	5.8	18,461	110	348,279	19	4.3	3,173
85 and older	1,790	59.0	5.9	17,863	103	313,068	18	4.6	3,033
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Basis of Eligibility ^c									
Aged	4,957	56.4	5.8	51,022	108	951,571	19	4.4	8,786
Disabled	4,040	53.7	5.6	42,468	117	882,399	21	3.2	7,526
Adults	672	57.6	7.9	9,244	113	132,150	14	4.2	1,166
Children	2	33.3	2.7	16	85	511	32	3.4	6
Unknown	0	0.0	0.0	0	0	0	0	0.0	2
Gender									
Female	6,705	60.2	6.6	73,683	127	1,420,010	19	4.1	11,144
Male	2,966	46.8	4.6	29,067	86	546,621	19	3.0	6,342
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
Race									
White	8,868	56.8	6.1	95,562	118	1,845,880	19	3.8	15,605
African American	30	47.6	3.6	229	57	3,582	16	1.8	63
Other/unknown	773	42.5	3.8	6,959	64	117,169	17	2.9	1,818
Use of Nursing									
Facilities ^d									
Entire year	1,972	61.9	7.2	22,922	144	457,828	20	4.3	3,185
Part year	1,037	68.3	6.4	9,678	120	182,780	19	4.4	1,519
None	6,662	52.1	5.5	70,150	104	1,326,023	19	3.5	12,782
Maintenance									
Assistance Status									
Cash	3,010	49.0	4.6	28,195	95	583,405	21	3.5	6,139
Medically needy	4,896	59.6	6.4	52,401	123	1,013,302	19	3.9	8,219
Poverty related	10	52.6	2.4	46	53	1,011	22	4.5	19
Other/unknown	1,755	56.4	7.1	22,108	119	368,913	17	3.8	3,109

Table D11

Dual Eligible Beneficiaries

- a. Table D.11 includes the beneficiaries represented by Cell G of Table 1. Beneficiaries include all dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.12

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

AMONG DUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC^{a,b}

MONTANA, 2004

Beneficiary	Number Rx per	Rx \$ per Benefit	• -	Barbiturate \$ per Be		Number of Benefit
Characteristics	Benefit Month	Month	\$ per Rx	Benefit Month	Benefit Month	Months
All	0.6	\$11	\$19	\$0	\$4	171,512
Age						
5 and younger	0.0	0	0	0	0	0
6-14	0.4	18	44	0	0	72
15-20	0.1	4	29	0	2	327
21-44	0.4	8	19	0	4	33,391
45-64	0.7	14	20	0	5	45,088
65-74	0.6	12	20	0	3	33,807
75-84	0.6	12	19	0	3	30,262
85 and older	0.6	11	18	0	2	28,565
Unknown	0.0	0	0	0	0	0
Basis of Eligibility ^c						
Aged	0.6	11	19	0	3	82,953
Disabled	0.6	12	21	0	5	74,785
Adults	0.7	10	14	0	3	13,688
Children	0.2	8	32	0	8	66
Unknown	0.0	0	0	0	0	20
Gender						
Female	0.7	13	19	0	4	110,726
Male	0.5	9	19	0	3	60,786
Unknown	0.0	0	0	0	0	0
Race						
White	0.6	12	19	0	4	152,220
African American	0.4	6	16	0	2	609
Other/unknown	0.4	6	17	0	2	18,683
Use of Nursing						
Facilities ^d						
Entire year	0.7	14	20	0	3	32,298
Part year	0.7	14	19	0	4	13,384
None	0.6	11	19	0	4	125,830
Maintenance						
Assistance Status						
Cash	0.4	9	21	0	3	66,849
Medically needy	0.7	14	19	0	4	70,719
Poverty related	0.3	7	22	0	4	138
Other/unknown	0.7	11	17	0	3	33,806

- a. Table D.12 includes the beneficiaries represented by Cell G of Table 1. Beneficiaries include all dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004.
- b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.
- c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.
- d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE D.13

USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D

FOR SELECTED DRUG CATEGORIES AMONG DUALS^{a,b,c}

MONTANA, 2004

				Rx \$ as a Percentage of All Part D			Number Rx as a Percentage of All Part D
Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Excluded Rx \$	Total Number Rx.	\$ per Rx	Excluded Rx
All	15,496	\$127	\$1,966,631	100.0 %	102,750	\$19	100.0 %
Anorexia or weight loss/gain	1	7	7	0.0	1	7	0.0
Fertility drugs	1	47	47	0.0	1	47	0.0
Drugs for cosmetic purposes	8	13	106	0.0	11	10	0.0
Cough and cold medications	1,710	70	119,132	6.1	4,421	27	4.3
Vitamins and minerals	3,516	148	520,292	26.5	26,385	20	25.7
Non-prescription drugs	5,323	114	604,758	30.8	35,411	17	34.5
Barbiturates	172	116	19,930	1.0	1,957	10	1.9
Benzodiazepines	4,428	137	604,492	30.7	33,077	18	32.2
Other Part D Excl Rx Drugs	337	290	97,867	5.0	1,486	66	1.4

Source: Data for this table are from the MAX 2004 file for Montana, released by CMS in 12/2007. This table was produced on 03/25/2008.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

a. Table D.13 includes the beneficiaries represented by Cell G of Table 1. Beneficiaries include all dual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2004. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2004. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table D11.

SUPPLEMENTAL TABLE 1 MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES^{a, b} MONTANA, 2004

Total Number of Dual Eligible Beneficiaries

Total Pharmacy Reimbursement for Dual Eligible Beneficiaries

Mean Pharmacy Reimbursement per Dual Eligible Beneficiary

17,486 \$52,510,703 \$3,003

Annual Pharmacy Reimbursement per				Percent of Total Pharmacy
Beneficiary	Number of Beneficiaries	Percent of Dual Beneficiaries	Pharmacy Reimbursement	Reimbursement
\$0	2,233	12.8 %	\$0	0.0 %
1-500	3,146	18.0	644,634	1.2
501-1,000	1,771	10.1	1,307,451	2.5
1,001-1,500	1,447	8.3	1,792,102	3.4
1,501-2,000	1,163	6.7	2,024,203	3.9
2,001-2,500	1,009	5.8	2,256,022	4.3
2,501-3,000	903	5.2	2,472,313	4.7
3,001-3,500	782	4.5	2,536,470	4.8
3,501-4,000	627	3.6	2,354,292	4.5
4,001-4,500	598	3.4	2,539,006	4.8
4,501-5,000	502	2.9	2,381,809	4.5
5,001-5,500	431	2.5	2,257,426	4.3
5,501-6,000	320	1.8	1,835,419	3.5
6,001-6,500	301	1.7	1,883,075	3.6
6,501-7,000	276	1.6	1,859,669	3.5
7,001-7,500	234	1.3	1,696,829	3.2
7,501-8,000	206	1.2	1,593,254	3.0
8,001-8,500	137	0.8	1,130,476	2.2
8,501-9,000	138	0.8	1,207,371	2.3
9,001-9,500	143	0.8	1,324,253	2.5
9,501-10,000	113	0.6	1,103,888	2.1
10,001+	1,006	5.8	16,310,741	31.1

Source: Data for this table are from the MAX 2004 file for Montana, released by CMS in 12/2007. This table was produced on 03/25/2008.

Supp Table 1 10/16/2008

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2004.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

SUPPLEMENTAL TABLE 1A MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE $65^{a, b, c}$ MONTANA, 2004

Total Number of Disabled Dual Eligible Beneficiaries, Age < 65

Total Pharmacy Reimbursement for Disabled Dual Eligible Beneficiaries, Age < 65

Mean Pharmacy Reimbursement per Disabled Dual Eligible Beneficiary, Age < 65

6,677 \$25,660,736 \$3,843

Annual Pharmacy Reimbursement	Percent of	Disabled Dual Beneficiaries,		Percent of Total Pharmacy
per Beneficiary	Number of Beneficiaries	Age < 65	Pharmacy Reimbursement	Reimbursement
\$0	938	14.0 %	0	0.0 %
1-500	1,288	19.3	246,652	1.0
501-1,000	584	8.7	424,915	1.7
1,001-1,500	449	6.7	557,275	2.2
1,501-2,000	331	5.0	576,521	2.2
2,001-2,500	316	4.7	703,787	2.7
2,501-3,000	270	4.0	737,453	2.9
3,001-3,500	241	3.6	782,292	3.0
3,501-4,000	205	3.1	771,134	3.0
4,001-4,500	183	2.7	777,539	3.0
4,501-5,000	158	2.4	749,704	2.9
5,001-5,500	167	2.5	875,909	3.4
5,501-6,000	123	1.8	706,303	2.8
6,001-6,500	128	1.9	801,954	3.1
6,501-7,000	113	1.7	762,054	3.0
7,001-7,500	91	1.4	661,064	2.6
7,501-8,000	91	1.4	705,595	2.7
8,001-8,500	71	1.1	585,321	2.3
8,501-9,000	75	1.1	656,613	2.6
9,001-9,500	79	1.2	731,077	2.8
9,501-10,000	61	0.9	595,486	2.3
10,001+	715	10.7	12,252,088	47.7

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2004.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

c. This table is limited to dual eligible beneficiaries who were under age 65 and also indicated as disabled in the MAX files. Therefore, dual eligible beneficiaries under age 65 in "adults" or "children" basis-of-eligibility categories in Table D.2 are excluded because they were not classified as disabled in the MAX files. Disabled dual eligible beneficiaries age 65 and older are included in Supplemental Tables 1B through 1E, depending on their age.

SUPPLEMENTAL TABLE 1B MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER^{a, b} MONTANA, 2004

Total Number of Dual Eligible Beneficiaries, Age 65+
Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 65+
Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 65+

9,731 \$23,894,605 \$2,456

Annual Pharmacy Reimbursement				Percent of Total Pharmacy
per Beneficiary	Number of Beneficiaries	Percent of Dual Beneficiaries, Age 65+	Pharmacy Reimbursement	Reimbursement
\$0	1,205	12.4 %	0	0.0 %
1-500	1,631	16.8	354,168	1.5
501-1,000	1,063	10.9	790,162	3.3
1,001-1,500	888	9.1	1,101,575	4.6
1,501-2,000	749	7.7	1,301,843	5.4
2,001-2,500	636	6.5	1,425,729	6.0
2,501-3,000	583	6.0	1,597,813	6.7
3,001-3,500	487	5.0	1,581,195	6.6
3,501-4,000	397	4.1	1,489,175	6.2
4,001-4,500	390	4.0	1,654,864	6.9
4,501-5,000	317	3.3	1,502,924	6.3
5,001-5,500	237	2.4	1,239,989	5.2
5,501-6,000	176	1.8	1,008,086	4.2
6,001-6,500	157	1.6	981,636	4.1
6,501-7,000	145	1.5	975,912	4.1
7,001-7,500	123	1.3	891,132	3.7
7,501-8,000	95	1.0	733,562	3.1
8,001-8,500	59	0.6	487,602	2.0
8,501-9,000	53	0.5	463,040	1.9
9,001-9,500	50	0.5	462,534	1.9
9,501-10,000	44	0.5	430,345	1.8
10,001+	246	2.5	3,421,319	14.3

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2004.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

SUPPLEMENTAL TABLE 1C MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74 $^{\rm a,\,b}$ MONTANA, 2004

Total Number of Dual Eligible Beneficiaries, Age 65-74
Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 65-74
Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 65-74

3,525 \$9,006,281 \$2,555

Annual Pharmacy Reimbursement per				Percent of Total Pharmacy
Beneficiary	Number of Beneficiaries	Percent of Dual Beneficiaries, Age 65-74	Pharmacy Reimbursement	Reimbursement
\$0	608	17.2 %	0	0.0 %
1-500	613	17.4	124,273	1.4
501-1,000	342	9.7	252,594	2.8
1,001-1,500	260	7.4	322,463	3.6
1,501-2,000	241	6.8	417,773	4.6
2,001-2,500	188	5.3	418,048	4.6
2,501-3,000	178	5.0	488,612	5.4
3,001-3,500	162	4.6	528,080	5.9
3,501-4,000	139	3.9	521,010	5.8
4,001-4,500	121	3.4	514,322	5.7
4,501-5,000	109	3.1	516,851	5.7
5,001-5,500	66	1.9	344,224	3.8
5,501-6,000	59	1.7	338,654	3.8
6,001-6,500	55	1.6	344,548	3.8
6,501-7,000	68	1.9	458,561	5.1
7,001-7,500	42	1.2	304,919	3.4
7,501-8,000	36	1.0	277,633	3.1
8,001-8,500	17	0.5	139,839	1.6
8,501-9,000	31	0.9	269,768	3.0
9,001-9,500	25	0.7	230,270	2.6
9,501-10,000	27	0.8	264,565	2.9
10,001+	138	3.9	1,929,274	21.4

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2004.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

SUPPLEMENTAL TABLE 1D MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO $84^{a,\,b}$ MONTANA, 2004

Total Number of Dual Eligible Beneficiaries, Age 75-84

Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 75-84

Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 75-84

3,173 \$8,086,494 \$2,549

Annual Pharmacy Reimbursement per				Percent of Total Pharmacy
Beneficiary	Number of Beneficiaries	Percent of Dual Beneficiaries, Age 75-84	Pharmacy Reimbursement	Reimbursement
\$0	397	12.5 %	0	0.0 %
1-500	502	15.8	109,972	1.4
501-1,000	317	10.0	237,581	2.9
1,001-1,500	275	8.7	345,875	4.3
1,501-2,000	243	7.7	424,466	5.2
2,001-2,500	215	6.8	481,963	6.0
2,501-3,000	203	6.4	554,613	6.9
3,001-3,500	158	5.0	513,224	6.3
3,501-4,000	127	4.0	477,531	5.9
4,001-4,500	133	4.2	564,611	7.0
4,501-5,000	120	3.8	567,544	7.0
5,001-5,500	90	2.8	471,845	5.8
5,501-6,000	59	1.9	337,197	4.2
6,001-6,500	62	2.0	386,962	4.8
6,501-7,000	42	1.3	282,398	3.5
7,001-7,500	46	1.4	332,842	4.1
7,501-8,000	39	1.2	302,161	3.7
8,001-8,500	30	0.9	247,919	3.1
8,501-9,000	13	0.4	113,764	1.4
9,001-9,500	13	0.4	121,313	1.5
9,501-10,000	12	0.4	116,679	1.4
10,001+	77	2.4	1,096,034	13.6

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2004.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

SUPPLEMENTAL TABLE 1E MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER^{a, b} MONTANA, 2004

Total Number of Dual Eligible Beneficiaries, Age 85+
Total Pharmacy Reimbursement for Dual Eligible Beneficiaries, Age 85+
Mean Pharmacy Reimbursement per Dual Eligible Beneficiary, Age 85+

3,033 \$6,801,830 \$2,243

Annual Pharmacy Reimbursement per				Percent of Total Pharmacy
Beneficiary	Number of Beneficiaries	Percent of Dual Beneficiaries, Age 85+	Pharmacy Reimbursement	Reimbursement
\$0	200	6.6 %	0	0.0 %
1-500	516	17.0	119,923	1.8
501-1,000	404	13.3	299,987	4.4
1,001-1,500	353	11.6	433,237	6.4
1,501-2,000	265	8.7	459,604	6.8
2,001-2,500	233	7.7	525,718	7.7
2,501-3,000	202	6.7	554,588	8.2
3,001-3,500	167	5.5	539,891	7.9
3,501-4,000	131	4.3	490,634	7.2
4,001-4,500	136	4.5	575,931	8.5
4,501-5,000	88	2.9	418,529	6.2
5,001-5,500	81	2.7	423,920	6.2
5,501-6,000	58	1.9	332,235	4.9
6,001-6,500	40	1.3	250,126	3.7
6,501-7,000	35	1.2	234,953	3.5
7,001-7,500	35	1.2	253,371	3.7
7,501-8,000	20	0.7	153,768	2.3
8,001-8,500	12	0.4	99,844	1.5
8,501-9,000	9	0.3	79,508	1.2
9,001-9,500	12	0.4	110,951	1.6
9,501-10,000	5	0.2	49,101	0.7
10,001+	31	1.0	396,011	5.8

a. This table is based on prescription drug claims for beneficiaries who had Medicare as well as Medicaid fee-for-service pharmacy benefit coverage during some or all months of Medicaid enrollment in 2004.

b. Medicaid reimbursement amounts in this table do not reflect federally required rebates from drug manufacturers to states.

APPENDIX TABLE A.3
CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY^{a, b}
DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

Beneficiary	Number of Beneficiaries						Number of Benefit Months						
Characteristics	All	Aged	Disabled	Adults	Children	Unknown		All	Aged	Disabled	Adults	Children	Unknown
All	17,486	8,786	7,526	1,166	6	2		171,512	82,953	74,785	13,688	66	20
Age													
5 and younger	0	0	0	0	0	0			0	0	0	0	0
6-14	6	0	6	0	0	0		72	0	72	0	0	0
15-20	29	0	24	0	5	0		327	0	267	0	60	0
21-44	3,189	3	2,626	559	1	0		33,391	36	26,857	6,492	6	0
45-64	4,531	6	4,021	502	0	2	0	45,088	72	39,036	5,960	0	20
65-74	3,525	2,742	712	71	0	0		33,807	25,798	7,179	830	0	0
75-84	3,173	3,028	115	30	0	0		30,262	28,734	1,170	358	0	0
85 and older	3,033	3,007	22	4	0	0		28,565	28,313	204	48	0	0
Unknown	0	0	0	0	0	0			0	0	0	0	0
Gender													
Female	11,144	6,480	4,096	564	2	2		110,726	62,669	41,441	6,572	24	20
Male	6,342	2,306	3,430	602	4	0	0	60,786	20,284	33,344	7,116	42	0
Unknown	0	0	0	0	0	0			0	0	0	0	0
Race													
White	15,605	7,986	6,535	1,076	6	2		152,220	74,994	64,498	12,642	66	20
African American	63	19	41	3	0	0	0	609	176	397	36	0	0
Other/unknown	1,818	781	950	87	0	0		18,683	7,783	9,890	1,010	0	0
Use of Nursing Facilities ^c													
Entire year	3,185	2,875	310	0	0	0		32,298	28,897	3,401	0	0	0
Part year	1,519	1,282	216	21	0	0		13,384	11,071	2,066	247	0	0
None	12,782	4,629	7,000	1,145	6	2		125,830	42,985	69,318	13,441	66	20
Maintenance Assistance Status													
Cash	6,139	1,871	4,255	13	0	0		66,849	20,674	46,054	121	0	0
Medically needy	8,219	5,785	2,434	0	0	0		70,719	50,816	19,903	0	0	0
Poverty related	19	0	0	17	0	2		138	0	0	118	0	20
Other/unknown	3,109	1,130	837	1,136	6	0		33,806	11,463	8,828	13,449	66	0
Dual Status ^d													
Full dual, all year	17,486	8,786	7,526	1,166	6	2		171,512	82,953	74,785	13,688	66	20
Full dual, part year	0	0	0	0	0	0			0	0	0	0	0
Managed Care (MC) Status													
Fee-for-service (FFS) all year	17,486	8,786	7,526	1,166	6	2		171,512	82,953	74,785	13,688	66	20
FFS part year, with Rx claims	0	0	0	0	0	0	0		0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0			0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0			0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0			0	0	0	0	0

0

Appendix Table A.3

- a. Table A.3 includes the beneficiaries represented by Cell F of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.
- b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.
- c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.
- d. The "Full dual, all year" group contains beneficiaries who had Medicare as well as Medicaid pharmacy benefits during all months of Medicaid enrollment in 2004. The "Full dual, part year" group contains beneficiaries who had such benefits for some, but not all, months of their enrollment. Refer to footnote g of Table 1 for more information about how we determined dual eligibility status.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.4

MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS^a DUAL ELIGIBLE BENEFICIARIES, MONTANA, 2004

Beneficiary	Beneficiaries Benefit Months in Cell		Included in Cell G o	f Table 1	Excluded from Cell G of Table 1		
Characteristics	Number of Nur Beneficiaries	nber of Benefit Months	Number of Nur Beneficiaries	nber of Benefit Months	Number of Num Beneficiaries	nber of Benefit Months	
All	17,486	171,512	17,486	171,512	0	0	
Fee-for-service (FFS) all year	17,486	171,512	17,486	171,512	0	0	
FFS part year, with Rx claims	0	0	0	0	0	0	
FFS part year, with no Rx claims	0	0	0	0	0	0	
Managed care (MC) all year, with Rx claims	0	0	0	0	0	0	
MC all year, with no Rx claims	0	0	0	0	0	0	

Source: Data for this table are from the MAX 2004 file for Montana, released by CMS in 12/2007. This table was produced on 03/25/2008.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare and Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.